Californian biopharma, TwoXAR, which is using a computational platform to identify drug candidates, de-risks opportunities through preclinical studies, and progresses drug candidates into the clinic, has raised $10m through a series A financing round.
Artificial intelligence-driven biopharma company twoXAR Inc. has raised $10m via a series A financing, led by SoftBank Ventures, to grow and advance its in-house preclinical pipeline.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
